Literature DB >> 17101317

Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.

Saara Ollila1, Laura Sarantaus, Reetta Kariola, Philip Chan, Heather Hampel, Elke Holinski-Feder, Finlay Macrae, Maija Kohonen-Corish, Anne-Marie Gerdes, Päivi Peltomäki, Elisabeth Mangold, Albert de la Chapelle, Marc Greenblatt, Minna Nyström.   

Abstract

BACKGROUND & AIMS: Inherited deleterious mutations in mismatch repair genes MLH1, MSH2, and MSH6 predispose to hereditary nonpolyposis colorectal cancer. A major diagnostic challenge is the difficulty in evaluating the pathogenicity of missense mutations. Previously we showed that most missense variants in MSH6 do not impair MMR capability and are associated with no or low cancer susceptibility, whereas in MLH1, functional studies distinguished nontruncating mutations with severe defects from those not or slightly impaired in protein expression or function. The present study was undertaken to evaluate the pathogenicity of inherited missense mutations in MSH2.
METHODS: Fifteen mutated MSH2 proteins including 14 amino acid substitutions and one in-frame deletion were tested for expression/stability, MSH2/MSH6 interaction, and repair efficiency. The genetic and biochemical data were correlated with the clinical data. Comparative sequence analysis was performed to assess the value of sequence homology as a tool for predicting functional results.
RESULTS: None of the studied MSH2 mutations destroyed the protein or abolished MSH2/MSH6 interaction, whereas 12 mutations impaired the repair capability of the protein. Comparative sequence analysis correctly predicted functional studies for 13 of 14 amino acid substitutions.
CONCLUSIONS: Interpretation was pathogenic for 12, nonpathogenic for 2, and contradictory for 1 mutation. The pathogenicity could not be distinguished unambiguously by phenotypic characteristics, although correlation between the absence of staining for MSH2 and pathogenicity of the missense mutation was notable. Unlike in MSH6 and MLH1, the pathogenicity of missense mutations in MSH2 was always associated with impaired repair capability of the mutated protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101317     DOI: 10.1053/j.gastro.2006.08.044

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.

Authors:  Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2015-12-02

2.  Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Authors:  Brian H Shirts; Eric Q Konnick; Sarah Upham; Tom Walsh; John Michael O Ranola; Angela L Jacobson; Mary-Claire King; Rachel Pearlman; Heather Hampel; Colin C Pritchard
Journal:  Am J Hum Genet       Date:  2018-06-07       Impact factor: 11.025

3.  Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients.

Authors:  Lise Lotte Christensen; Reetta Kariola; Mari K Korhonen; Friedrik P Wikman; Lone Sunde; Anne-Marie Gerdes; Henrik Okkels; Carsten A Brandt; Inge Bernstein; Thomas V O Hansen; Rikke Hagemann-Madsen; Claus L Andersen; Minna Nyström; Torben F Ørntoft
Journal:  Fam Cancer       Date:  2009-08-21       Impact factor: 2.375

4.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

5.  A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Authors:  Francesca Bianchi; Elena Maccaroni; Laura Belvederesi; Cristiana Brugiati; Riccardo Giampieri; Federica Bini; Raffaella Bracci; Silvia Pagliaretta; Michela Del Prete; Francesco Piva; Alessandra Mandolesi; Marina Scarpelli; Rossana Berardi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

6.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.

Authors:  Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels
Journal:  Fam Cancer       Date:  2008-06-20       Impact factor: 2.375

8.  Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.

Authors:  Hellen Houlleberghs; Marleen Dekker; Hildo Lantermans; Roos Kleinendorst; Hendrikus Jan Dubbink; Robert M W Hofstra; Senno Verhoef; Hein Te Riele
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

9.  MutSbeta exceeds MutSalpha in dinucleotide loop repair.

Authors:  J Kantelinen; M Kansikas; M K Korhonen; S Ollila; K Heinimann; R Kariola; M Nyström
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

10.  Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions in vivo.

Authors:  Adam S Mastrocola; Christopher D Heinen
Journal:  Hum Mutat       Date:  2010-10       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.